Hutchison China MediTech Limited (HCM.L)
- Globe Newswire
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today provides a corporate and strategic update, following an in-depth evaluation of the business. In response to the challenging market conditions currently affecting the global biopharmaceutical sector, HUTCHMED has taken a numb
- Globe Newswire
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant — — Safety findings consistent with fruquintinib known profile — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces initial results from FRU
- Globe Newswire
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China. The first patient in China received the first dose on October 27, 2022. The study is a randomized, open-label, active-controlled study to evalu
